- Home
- NTRB vs VANI Comparison
NTRB vs VANI Comparison
Compare NTRB & VANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NTRB | VANI |
|---|---|---|
| Founded | 2016 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 71.7M | 81.2M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | NTRB | VANI |
|---|---|---|
| Price | $4.93 | $1.36 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $13.00 | $4.00 |
| AVG Volume (30 Days) | 23.0K | ★ 173.2K |
| Earning Date | 12-11-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,278,321.00 | N/A |
| Revenue This Year | $30.17 | N/A |
| Revenue Next Year | $3,394.36 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 12.69 | N/A |
| 52 Week Low | $3.72 | $0.91 |
| 52 Week High | $11.78 | $1.92 |
Technical Indicators
Market Signals| Indicator | NTRB | VANI |
|---|---|---|
| Relative Strength Index (RSI) | 40.95 | 45.64 |
| Support Level | $4.60 | $1.25 |
| Resistance Level | $5.45 | $1.55 |
| Average True Range (ATR) | 0.37 | 0.07 |
| MACD | 0.09 | 0.00 |
| Stochastic Oscillator | 43.86 | 40.07 |
Price Performance
Historical ComparisonAbout NTRB Nutriband Inc.
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.
About VANI Vivani Medical Inc. (DE)
Vivani Medical Inc is a preclinical-stage biopharmaceutical company. The company develops miniaturized, subdermal implants utilizing its proprietary NanoPortal technology to enable long-term, near-constant-rate delivery of a broad range of medicines to treat chronic diseases. It has two reporting segments, the Biopharm Division and the Neuromodulation Division. The Biopharm Division includes activities from NPM and Vivani Medical Australia Pty Ltd, and the Neurostimulation Division includes activities from Cortigent and its subsidiary in Switzerland.